Overview
Compare with PRF Technologies Ltd., SKINVISIBLE, INC. or Phio Pharmaceuticals Corp., or pick any stock.
- TickerBDPT on OTC1
- IndustryPharmaceutical Preparations1
- HeadquartersLas Vegas, Nevada1
- Incorporated inDE2
- Business address2620 Regatta Drive, Suite 102, Las Vegas, Nv 891282
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue8¢$5.8K
- Interest92¢$70.9K
Out of $18.3K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenues | $18.3K | $12.7K |
| Cost of revenue | $5.8K | $8.6K |
| Gross Profit | $12.5K | $4.0K |
| General and administrative | $820.5K | $335.3K |
| Professional fees | $230.2K | $169.5K |
| Impairment of inventory | $0 | $81.3K |
| Amortization and impairment loss of license and patent | $4.0K | $19.9K |
| Total Operating Expenses | $1.1M | $606.1K |
| Loss from operations | -$1.0M | -$602.1K |
| Other income | $0 | $5.0K |
| Interest expense | -$70.9K | -$92.0K |
| Change in fair value of derivative liabilities | -$578.6K | -$210.0K |
| Loss on settlement of debt | $133.8K | $0 |
| Total Other Income (Expense) | -$515.7K | -$297.1K |
| Loss before income taxes | -$1.6M | -$899.2K |
| Net Loss | -$1.6M | -$899.2K |
| Basic and Diluted | -$0.15 | -$0.11 |
| Basic and Diluted | 10.1M shares | 8.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $158.4K | $137.5K | $60.8K |
| Inventory | $44.7K | $19.1K | |
| Security deposit | $2.5K | $2.5K | |
| Prepaid expense | $6.2K | $100.0K | |
| Other receivable | $0 | $2.8K | |
| Total Current Assets | $211.9K | $261.9K | |
| License and patent, net | $14.0K | $0 | |
| TOTAL ASSETS | $225.9K | $261.9K | |
| Accounts payable and accrued liabilities | $232.7K | $179.5K | |
| Derivative liabilities | $1.7M | $1.1M | |
| Convertible notes | $352.3K | $461.0K | |
| Notes Payable | $32.1K | $32.1K | |
| Total Current Liabilities | $2.4M | $1.7M | |
| Total Liabilities | $2.4M | $1.7M | |
| Common stock ($.0001 par value, 1,250,000,000 shares authorized; 12,008,725 and 8,215,426 shares issued and outstanding as of December 31, 2025 and 2024, and 66 issuable, respectively) | $1.2K | $821 | |
| Additional paid-in capital | $8.6M | $7.7M | |
| Subscription receivable | -$5.9K | -$5.9K | |
| Accumulated deficit | -$10.7M | -$9.2M | |
| Total Stockholders' Deficit | -$2.1M | -$1.5M | -$1.6M |
| Liabilities and Equity | $225.9K | $261.9K | |
| Preferred stock, shares par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 31.0M shares | 31.0M shares | |
| Common stock, shares par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.2B shares | 1.2B shares | |
| Common stock, shares issued | 12.0M shares | 8.2M shares | |
| Common stock, shares outstanding | 12.0M shares | 8.2M shares | |
| Common stock, shares issuable | 66 shares | 66 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $158.4K | $137.5K | $60.8K |
| Inventory | $44.7K | $19.1K | |
| Security deposit | $2.5K | $2.5K | |
| Prepaid expense | $6.2K | $100.0K | |
| Other receivable | $0 | $2.8K | |
| Total Current Assets | $211.9K | $261.9K | |
| License and patent, net | $14.0K | $0 | |
| TOTAL ASSETS | $225.9K | $261.9K | |
| Accounts payable and accrued liabilities | $232.7K | $179.5K | |
| Derivative liabilities | $1.7M | $1.1M | |
| Convertible notes | $352.3K | $461.0K | |
| Notes Payable | $32.1K | $32.1K | |
| Total Current Liabilities | $2.4M | $1.7M | |
| Total Liabilities | $2.4M | $1.7M | |
| Common stock ($.0001 par value, 1,250,000,000 shares authorized; 12,008,725 and 8,215,426 shares issued and outstanding as of December 31, 2025 and 2024, and 66 issuable, respectively) | $1.2K | $821 | |
| Additional paid-in capital | $8.6M | $7.7M | |
| Subscription receivable | -$5.9K | -$5.9K | |
| Accumulated deficit | -$10.7M | -$9.2M | |
| Total Stockholders' Deficit | -$2.1M | -$1.5M | -$1.6M |
| Liabilities and Equity | $225.9K | $261.9K | |
| Preferred stock, shares par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 31.0M shares | 31.0M shares | |
| Common stock, shares par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 1.2B shares | 1.2B shares | |
| Common stock, shares issued | 12.0M shares | 8.2M shares | |
| Common stock, shares outstanding | 12.0M shares | 8.2M shares | |
| Common stock, shares issuable | 66 shares | 66 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$1.6M | -$899.2K |
| Change in fair value of derivative liabilities | $578.6K | $210.0K |
| Bad debt | $2.9K | $0 |
| Impairment of patent | $0 | $18.0K |
| Impairment of inventory | $0 | $81.3K |
| Amortization of license and patent | $0 | $1.9K |
| Amortization of debt discount | $25.1K | $52.6K |
| Management compensation | $443.7K | $208.9K |
| Depreciation | $4.0K | $0 |
| Gain on settlement of debt | -$133.8K | $0 |
| Accounts receivable | -$59 | $0 |
| Inventory | -$25.6K | -$25.2K |
| Prepaid expense | $93.8K | $57.2K |
| Accounts payable and accrued liabilities | $53.3K | $44.8K |
| Net Cash Used in Operating Activities | -$516.0K | -$249.5K |
| Purchase property and equipment's | -$18.0K | $0 |
| Net Cash Used in Investing Activities | -$18.0K | $0 |
| Proceeds from issuance of Series D Preferred Stock | $300.0K | $294.1K |
| Proceeds from notes payable | $0 | $32.1K |
| Proceeds from convertible notes | $255.0K | $0 |
| Net Cash Provided by Financing Activities | $555.0K | $326.2K |
| Net change in cash | $21.0K | $76.7K |
| Cash paid for income taxes | $0 | $0 |
| Cash paid for interest | $0 | $0 |
| Derivative liability recognized as debt discount | $255.0K | $0 |
| Issuance of common stock for conversion of debt | $148.1K | $202.6K |
| Issuance of common stock for conversion of debt | $150.0K | $0 |
| Issuance of Series A preferred stock for license fee | $0 | $1.5K |
| Issuance of Series B preferred stock for license fee | $0 | $3.0K |
| Issuance of Series B preferred stock for settlement of debt - related party | $0 | $1.5K |
| Issuance of Series C preferred stock for license fee | $0 | $60.0K |
| Convertible note issued for consulting service | $0 | $150.0K |
| Debt forgiveness | $0 | $310.2K |
No quarter-by-quarter statement was filed.
Corporate structure
BIOADAPTIVES, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of BIOADAPTIVES, INC.
- Azuna Health LLC Filed SC 13D on BIOADAPTIVES, INC., latest Oct 22, 2024
- James Keener Filed SC 13D on BIOADAPTIVES, INC., latest Oct 22, 2024
- BIOADAPTIVES, INC. Las Vegas, Nevada
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What BIOADAPTIVES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $215.2K4 Dec 31, 2025 | $261.9K4 Dec 31, 2024 | −17.8% |
| Marketable securities, current | $04 Dec 31, 2025 | $04 Dec 31, 2024 |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Intangible assets, net (excluding goodwill) | $14.0K4 Dec 31, 2025 | $04 Dec 31, 2024 | |
| Finite-lived intangibles, gross | $24.5K9 Dec 31, 2024 | $25.4K9 Dec 31, 2023 | −3.7% |
| Accumulated amortization | $24.5K9 Dec 31, 2024 | $10.0K9 Dec 31, 2023 | +145.3% |
| Finite-lived intangibles, net | $09 Dec 31, 2024 | $15.4K9 Dec 31, 2023 | −100.0% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $44.7K4 Dec 31, 2025 | $19.1K4 Dec 31, 2024 | +133.9% |
| Raw materials | $9.5K4 Dec 31, 2025 | $19.1K4 Dec 31, 2024 | −50.3% |
| Finished goods | $35.2K4 Dec 31, 2025 | $04 Dec 31, 2024 |
Properties, in its own words
The Company currently maintains a physical address at 2620 Regatta Dr, Suite 102, Las Vegas, NV 89128. The Company does not currently maintain any other office facilities and does not anticipate the need to maintain office facilities at any time in the foreseeable future.
Item 2 of the 10-K filed Apr 14, 2026.3
Leadership
Who has led BIOADAPTIVES, INC., and when. Pick a name to see everywhere that person has worked.
- Chief executive officerGerald Epling Jul 23, 2013 to Jul 23, 201312
- Chief financial officerGerald Epling Jul 23, 2013 to Jul 23, 201312
Board members and other officers (4)
- Board memberMark P. Frissora May 5, 2025 to now13
- Board memberGimhana Sasanka Dissanayake Dec 3, 2024 to Dec 3, 202414
- Board memberGerald Epling Jul 23, 2013 to Jul 23, 201312
- Board memberBarry Epling Aug 13, 2013 to Jan 17, 201415
Former names
- APEX 8 Inc.May 3, 2013 to Aug 19, 20132
Timeline
- Mar 18, 20258-K Regulation FD disclosure16
- Feb 7, 20258-K Executive or director change17
- Dec 5, 20248-K Regulation FD disclosure18
- Nov 27, 20248-K Regulation FD disclosure19
- Nov 20, 20248-K Regulation FD disclosure; Other events20
- Oct 30, 20248-K Regulation FD disclosure; Other events21
- May 22, 20248-K Executive or director change; Regulation FD disclosure22
- May 14, 20248-K Change of auditor23
- Apr 6, 20238-K Executive or director change; Bylaws or fiscal year changed24
- Jun 14, 20228-K Regulation FD disclosure25
- Feb 3, 20228-K Entered a material agreement; Regulation FD disclosure26
- Jan 21, 20228-K Regulation FD disclosure27
- Jul 23, 2013New chief executive Gerald Epling becomes CEO12
Filings
88 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 13 major events, 21 insider forms, 2 large holders, 32 other. The latest 20:
- Oct 6, 20264 EDGAR
- Sep 3, 20264 EDGAR
- Aug 19, 202610-Q EDGAR
- Aug 14, 2026NT 10-Q EDGAR
- Aug 4, 20264 EDGAR
- Jul 6, 20264 EDGAR
- Jun 3, 20264 EDGAR
- May 15, 202610-Q EDGAR
- May 5, 20264 EDGAR
- Apr 14, 202610-K EDGAR
- Apr 3, 20264 EDGAR
- Mar 31, 2026NT 10-K EDGAR
- Mar 3, 20264 EDGAR
- Feb 3, 20264 EDGAR
- Jan 5, 20264 EDGAR
- Dec 3, 20254 EDGAR
- Nov 14, 202510-Q EDGAR
- Nov 4, 20254 EDGAR
- Oct 6, 20254 EDGAR
- Sep 3, 20254 EDGAR
The 88 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | Dissanayake Gimhana SasankaDirector | Buy | 125,000 | $0.09 | $11.2K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Azuna Health LLCSC 13D, 1 filing Oct 22, 202428
- James KeenerSC 13D, 1 filing Oct 22, 202429
SEC filer profile
How BIOADAPTIVES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARBIOADAPTIVES, INC.1
- CIK0001575142
- Employer ID (EIN)46-25922283
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address2620 Regatta Drive, Suite 102, Las Vegas, NV 891281
- Phone(702) 659-88291
- Shares outstanding196,926,762 as of Aug 13, 202611
- Public float$252.2K as of Dec 31, 20253
- AuditorBOLADALE LAWAL & CO., Lagos, Nigeria PCAOB ID 69933
- On EDGAR sinceMay 3, 20131
- Filings174 in all: 10-Q (33), 8-K (30), 4 (23), NT 10-Q (11), UPLOAD (11), 10-K (10), NT 10-K (6), 3 (5)1
All 31 form types
CORRESP (5), DEF 14C (5), 1-A POS (3), 10-12G/A (3), PRE 14C (3), SC 13D (3), 1-A (2), 1-A/A (2), 10-12G (2), 10-Q/A (2), 424B3 (2), QUALIF (2), 1-Z (1), 10-K/A (1), 15-15D (1), 253G1 (1), 8-K/A (1), D (1), EFFECT (1), S-1 (1), S-1/A (1), SC 13D/A (1), SEC STAFF ACTION (1)
- Latest filingsAnnual report (10-K) Apr 14, 2026
Quarterly report (10-Q) Aug 19, 2026
Latest 8-K (8-K) Mar 18, 2025
Risk factors and legal proceedings
The risks BIOADAPTIVES, INC. names in Item 1A of its 10-K filed Apr 14, 2026: 1 risk under these headings, as written.3
- RISKS RELATED TO OUR PUBLIC COMPANY STATUS AND OUR COMMON STOCK
Legal proceedings
The Company is not a party to any pending legal proceedings, and no such proceedings are known to be contemplated.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13SEC EDGARMark P. Frissora, Board member
- 14
- 15SEC EDGARBarry Epling, Board member
- 16SEC EDGARRegulation FD disclosure
- 17SEC EDGARExecutive or director change
- 18SEC EDGARRegulation FD disclosure
- 19SEC EDGARRegulation FD disclosure
- 20
- 21
- 22
- 23SEC EDGARChange of auditor
- 24
- 25SEC EDGARRegulation FD disclosure
- 26
- 27SEC EDGARRegulation FD disclosure
- 28
- 29